Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements


DOI: 10.1007/s10295-011-1082-9

Cite this article as:
Huang, CJ., Lin, H. & Yang, X. J Ind Microbiol Biotechnol (2012) 39: 383. doi:10.1007/s10295-011-1082-9


Nearly 30% of currently approved recombinant therapeutic proteins are produced in Escherichia coli. Due to its well-characterized genetics, rapid growth and high-yield production, E. coli has been a preferred choice and a workhorse for expression of non-glycosylated proteins in the biotech industry. There is a wealth of knowledge and comprehensive tools for E. coli systems, such as expression vectors, production strains, protein folding and fermentation technologies, that are well tailored for industrial applications. Advancement of the systems continues to meet the current industry needs, which are best illustrated by the recent drug approval of E. coli produced antibody fragments and Fc-fusion proteins by the FDA. Even more, recent progress in expression of complex proteins such as full-length aglycosylated antibodies, novel strain engineering, bacterial N-glycosylation and cell-free systems further suggests that complex proteins and humanized glycoproteins may be produced in E. coli in large quantities. This review summarizes the current technology used for commercial production of recombinant therapeutics in E. coli and recent advances that can potentially expand the use of this system toward more sophisticated protein therapeutics.


Escherichia coli Recombinant therapeutics production Aglycosylated antibody E. coli N-linked glycosylation Cell-free systems 

Copyright information

© Society for Industrial Microbiology and Biotechnology 2012

Authors and Affiliations

  1. 1.Cell Sciences & TechnologyAMGEN IncThousand OaksUSA

Personalised recommendations